eCite Digital Repository

Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection


Negishi, K and Negishi, T and Haluska, BA and Hare, JL and Plana, JC and Marwick, TH, Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection, European Heart Journal Cardiovascular Imaging, 15, (3) pp. 324-331. ISSN 2047-2404 (2014) [Refereed Article]

Copyright Statement

Copyright 2013 the authors

DOI: doi:10.1093/ehjci/jet159


Aims: The variability of ejection fraction (EF) poses a problem in the assessment of left ventricular (LV) function in patients receiving potentially cardiotoxic chemotherapy. We sought to use global longitudinal strain (GLS) to compare LV responses to various cardiotoxic chemotherapy regimens and to examine the response to cardioprotection with beta-blockers (BB) in patients showing subclinical myocardial damage.

Methods and Results We studied 159 patients (4914 year, 127 women) receiving anthracycline (group A, n=53, 4617 year), trastuzumab (group T, n=61, 5312 year), or trastuzumab after anthracyclines (group AT, n = 45, 46 9 year). LV indices [ejection fraction (EF), mitral annular systolic velocity, and GLS] were measured at baseline and follow-up (77 months). Patients who decreased GLS by ≥11% were followed for another 6 months; initiation of BB was at the discretion of the clinician. Anthracycline dose was similar between group A and group AT (213118 vs. 21647 mg/m2, P=0.85). Although ΔEF was similar among the groups, attenuation of GLS was the greatest in group AT (group A, 0.72.8% shortening; T, 1.12.7%; and AT, 2.02.3%; P=0.003, after adjustment). Of 52 patients who decreased GLS by ≥−11%, 24 were treated with BB and 28 were not. GLS improved in BB groups (from −17.62.3 to −19.82.6%, P<0.001) but not in non-BB groups (from −18.02.0 to −19.03.0%, P=0.08). Effects of BB were similar with all regimens.

Conclusions GLS is an effective parameter for identifying systolic dysfunction (which appears worst with combined anthracycline and trastuzumab therapy) and responds to cardioprotection in patients administered beta-blockers.

Item Details

Item Type:Refereed Article
Keywords:beta-blocker, cardiotoxicity, trastuzumab, anthracyclines, strain
Research Division:Biomedical and Clinical Sciences
Research Group:Cardiovascular medicine and haematology
Research Field:Cardiology (incl. cardiovascular diseases)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Negishi, K (Dr Kazuaki Negishi)
UTAS Author:Marwick, TH (Professor Tom Marwick)
ID Code:88021
Year Published:2014 (online first 2013)
Web of Science® Times Cited:154
Deposited By:Menzies Institute for Medical Research
Deposited On:2014-01-07
Last Modified:2017-10-31

Repository Staff Only: item control page